Correction due to missing pdf-file.
Bagsværd,
At the Annual General Meeting,
Resolutions adopted at the Annual General Meeting
Financial year 2020 and board remuneration
- Approval of the Company’s statutory Annual Report 2020 and distribution of profits according to the statutory Annual Report 2020.
- The final dividend for 2020 of
DKK 5.85 for each Novo Nordisk A or B share ofDKK 0.20 . The total dividend for 2020 ofDKK 9.10 includes both the interim dividend ofDKK 3.25 for each Novo Nordisk A and B share ofDKK 0.20 which was paid inAugust 2020 and the final dividend ofDKK 5.85 for each Novo Nordisk A and B share ofDKK 0.20 to be paid inMarch 2021 . - The Remuneration Report 2020 was approved (advisory vote).
- The actual remuneration of the Board of Directors for 2020 and the remuneration level for 2021 were approved.
Elections
- Re-election of
Helge Lund as chair of the Board of Directors. - Re-election of
Jeppe Christiansen as vice chair of the Board of Directors. - Re-election of
Laurence Debroux ,Andreas Fibig , Sylvie Grégoire,Kasim Kutay andMartin Mackay as members of the Board of Directors. - Election of
Henrik Poulsen as new member of the Board of Directors. - Appointment of
Deloitte Statsautoriseret Revisionspartnerselskab as the Company’s auditor.
Shares and capital
- Reduction of the Company’s B share capital by cancellation of part of the Company’s own holding of B shares. The Company’s B share capital is reduced by
DKK 8,000,000 fromDKK 362,512,800 toDKK 354,512,800 . The Company’s A share capital ofDKK 107,487,200 remains unchanged, whereby the Company’s share capital will amount toDKK 462,000,000 . - Authorisation to the Board of Directors until the Annual General Meeting 2022 to allow the Company to repurchase own shares of up to 10% of the share capital subject to a holding limit of 10% of the share capital.
- Cancellation of Article 5.3 of the company’s Articles of Association.
- Extension of the authorisation to the Board of Directors to increase the Company's share capital for a period of one year until
25 March 2023 up to nominallyDKK 46,200,000 .
Other
- Indemnification of Board members and executives from future liability in addition to any director’s and officer’s liability insurance.
- Amendments to the Remuneration Policy regarding international mobility, claw-back of variable pay, discretion to override the formulaic outcome under incentive programmes, capping of variable pay and incentive targets becoming obsolete.
- Amendments to the Articles of Association regarding an authorisation to hold future General Meetings as fully virtual and partially virtual meetings, the language in documents prepared for General Meetings and an ability to differentiate votes for certain shareholders.
- A proposal from a shareholder on making a plan for changed ownership of the Company was not adopted.
COVID-19 situation
Due to the current COVID-19 pandemic and in order to minimise the spread of the virus, the meeting was held as a fully virtual meeting. Accordingly, shareholders attended by electronic means and had been encouraged to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting.
Composition of the Board of Directors and its committees
After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees.
The Board of Directors, including its committees, is now composed as follows:
Helge Lund (chair of the Board and chair of the Nomination Committee)Jeppe Christiansen (vice chair of the Board and chair of the Remuneration Committee)Laurence Debroux (chair of the Audit Committee and member of the Remuneration Committee)Andreas Fibig (member of the Audit Committee)- Sylvie Grégoire (member of the Audit Committee, the Nomination Committee and the
Research & Development Committee ) - Mette Bøjer Jensen (employee representative and member of the Nomination Committee)
Kasim Kutay (member of the Nomination Committee and theResearch & Development Committee )Anne Marie Kverneland (employee representative and member of the Remuneration Committee)Martin Mackay (chair of theResearch & Development Committee and member of the Remuneration Committee)Henrik Poulsen (member of the Audit Committee)Thomas Rantzau (employee representative and member of theResearch & Development Committee )Stig Strøbæk (employee representative and member of the Audit Committee)
Further information
Media: | ||
+45 3079 3883 | mkd@novonordisk.com | |
+1 609 664 7308 | mzyb@novonordisk.com | |
Investors: | ||
Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
+45 3079 0301 | jvls@novonordisk.com | |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
+45 3079 4211 | mjhr@novonordisk.com | |
+1 609 235 2989 | krdb@novonordisk.com |
Company announcement No 21 / 2021
Attachment
- PR210325_AGM_Resolutions
© OMX, source